Monte Rosa Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
GLUE$10.50-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
| (in thousands, except share and per share amounts) | Three months endedSeptember 30, | Nine months ended September 30, | ||
|---|---|---|---|---|
| (unaudited) | 2024 | 2023 | 2024 | 2023 |
| Collaboration revenue | $9,216 | $— | $14,975 | $— |
| Operating expenses: | ||||
| Research and development | 27,616 | 28,306 | 82,697 | 84,137 |
| General and administrative | 8,127 | 8,662 | 26,394 | 24,311 |
| Total operating expenses | 35,743 | 36,968 | 109,091 | 108,448 |
| Loss from operations | (26,527) | (36,968) | (94,116) | (108,448) |
| Other income (expense): | ||||
| Interest income | 2,892 | 2,227 | 7,971 | 6,966 |
| Foreign currency exchange gain (loss), net | (153) | 27 | 414 | (151) |
| Gain on disposal of fixed assets | — | — | — | 24 |
| Loss on sale of marketable securities | — | — | — | (131) |
| Total other income | 2,739 | 2,254 | 8,385 | 6,708 |
| Net loss before income taxes | (23,788) | (34,714) | (85,731) | (101,740) |
| Provision for income taxes | (71) | (170) | (406) | (360) |
| Net loss | $(23,859) | $(34,884) | $(86,137) | $(102,100) |
| Net loss per share—basic and diluted | $(0.29) | $(0.70) | $(1.21) | $(2.06) |
| Weighted-average number of shares outstanding used in computing net loss per common share—basic and diluted | 82,011,670 | 49,814,903 | 71,173,647 | 49,533,143 |
| Comprehensive loss: | ||||
| Net loss | $(23,859) | $(34,884) | $(86,137) | $(102,100) |
| Other comprehensive income: | ||||
| Provision for pension benefit obligation | 37 | 14 | 107 | 42 |
| Unrealized gain on available-for-sale securities | 311 | 171 | 295 | 255 |
| Comprehensive loss | $(23,511) | $(34,699) | $(85,735) | $(101,803) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.